featured
Temporary Treatment Cessation vs Continuation of First-Line TKIs in Patients With Advanced Clear Cell RCC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Lancet Oncol 2023 Feb 13;[EPub Ahead of Print], JE Brown, KL Royle, W Gregory, C Ralph, A Maraveyas, O Din, T Eisen, P Nathan, T Powles, R Griffiths, R Jones, N Vasudev, M Wheater, A Hamid, T Waddell, R McMenemin, P Patel, J Larkin, G Faust, A Martin, J Swain, J Bestall, C McCabe, D Meads, V Goh, T Min Wah, J Brown, J Hewison, P Selby, F CollinsonFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.